Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6654871 | 0.87 | ADAM17 (0.43) | MAOBMAOAADAM17MMP9MMP13 | |
| SCHEMBL6662479 | 0.86 | ADAM17 (0.44) | MAOBMAOAADAM17MMP9MMP13 | |
| SCHEMBL6655286 | 0.86 | ADAM17 (0.51) | ALOX5ADAM17MMP9MMP13 | |
| SCHEMBL6656661 | 0.83 | ADAM17 (0.44) | ADAM17MMP9MMP13KMT2A | |
| SCHEMBL6656959 | 0.81 | ADAM17 (0.52) | ADAM17GAAMMP9MMP13KMT2A | |
| SCHEMBL6656714 | 0.81 | ADAM17 (0.45) | ADAM17MMP9MMP13 | |
| SCHEMBL6658036 | 0.77 | PSMB5 (0.39) | ADAM17MMP9MMP13 | |
| SCHEMBL6656469 | 0.74 | ADAM17 (0.56) | ADAM17MMP9MMP13 | |
| SCHEMBL6787626 | 0.73 | ALOX5 (0.49) | MAOBMAOAALOX5ADAM17RXRA | |
| SCHEMBL6656399 | 0.72 | ADAM17 (0.62) | ALOX5ADAM17MMP9MMP13KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147080-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | WYETH CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-10-10 | — | — | US | disclosed |
| EP-1147080-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044713-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | MMP12, MMP17, MMP14 | MAOB 1673/4885MAOA 1356/4885ALOX5 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.